These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 24013061)

  • 21. PCSK9 inhibitors reduce cardiovascular events, preliminary data show.
    Mayor S
    BMJ; 2015 Mar; 350():h1508. PubMed ID: 25782694
    [No Abstract]   [Full Text] [Related]  

  • 22. Hypercholesterolemia As a Risk Factor for Cardiovascular Disease: Current Controversial Therapeutic Management.
    Zárate A; Manuel-Apolinar L; Saucedo R; Hernández-Valencia M; Basurto L
    Arch Med Res; 2016 Oct; 47(7):491-495. PubMed ID: 28262189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs.
    Everett BM; Smith RJ; Hiatt WR
    N Engl J Med; 2015 Oct; 373(17):1588-91. PubMed ID: 26444323
    [No Abstract]   [Full Text] [Related]  

  • 24. Mipomersen: a safe and effective antisense therapy adjunct to statins in patients with hypercholesterolemia.
    Ricotta DN; Frishman W
    Cardiol Rev; 2012; 20(2):90-5. PubMed ID: 22293857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Lower LDL and/or raise HDL. In what direction is lipidology moving?].
    Parhofer KG
    MMW Fortschr Med; 2007 May; 149(22):27. PubMed ID: 18069222
    [No Abstract]   [Full Text] [Related]  

  • 26. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease.
    Stein EA; Dufour R; Gagne C; Gaudet D; East C; Donovan JM; Chin W; Tribble DL; McGowan M
    Circulation; 2012 Nov; 126(19):2283-92. PubMed ID: 23060426
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The current debate on lowering LDL cholesterol with ezetimibe].
    Erdmann E
    Dtsch Med Wochenschr; 2010 Sep; 135(36):1742. PubMed ID: 20812160
    [No Abstract]   [Full Text] [Related]  

  • 28. Antisense technology to lower LDL cholesterol.
    Neely RD; Bassendine MF
    Lancet; 2010 Mar; 375(9719):959-61. PubMed ID: 20227757
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy.
    Akdim F; Stroes ES; Sijbrands EJ; Tribble DL; Trip MD; Jukema JW; Flaim JD; Su J; Yu R; Baker BF; Wedel MK; Kastelein JJ
    J Am Coll Cardiol; 2010 Apr; 55(15):1611-8. PubMed ID: 20378080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Significant decline in the rate of cardiovascular incidents].
    Wedekind S
    MMW Fortschr Med; 2015 Jun; 157(11):66. PubMed ID: 26049360
    [No Abstract]   [Full Text] [Related]  

  • 31. How should we define hypercholesterolemia?
    Tonkin AM
    Curr Atheroscler Rep; 2000 Jul; 2(4):273-4. PubMed ID: 11122753
    [No Abstract]   [Full Text] [Related]  

  • 32. Liver histology during Mipomersen therapy for severe hypercholesterolemia.
    Hashemi N; Odze RD; McGowan MP; Santos RD; Stroes ESG; Cohen DE
    J Clin Lipidol; 2014; 8(6):606-611. PubMed ID: 25499943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 2013 ACC/AHA Guideline: a guideline for the population - without evidence from the population.
    Myerson M; Rosenson RS
    Cardiovasc Drugs Ther; 2014 Jun; 28(3):203-4. PubMed ID: 24610170
    [No Abstract]   [Full Text] [Related]  

  • 34. Preventing cardiovascular heart disease: Promising nutraceutical and non-nutraceutical treatments for cholesterol management.
    Johnston TP; Korolenko TA; Pirro M; Sahebkar A
    Pharmacol Res; 2017 Jun; 120():219-225. PubMed ID: 28408313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Risk patients are often insufficiently treated. LDL cholesterol to be held down even more vigorously].
    MMW Fortschr Med; 2004 Oct; 146(44):56-7. PubMed ID: 15566253
    [No Abstract]   [Full Text] [Related]  

  • 36. LDL cholesterol in CKD--to treat or not to treat?
    Massy ZA; de Zeeuw D
    Kidney Int; 2013 Sep; 84(3):451-6. PubMed ID: 23698234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel Therapies for Low-Density Lipoprotein Cholesterol Reduction.
    Toth PP
    Am J Cardiol; 2016 Sep; 118(6 Suppl):19A-32A. PubMed ID: 27620356
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia.
    Akdim F; Visser ME; Tribble DL; Baker BF; Stroes ES; Yu R; Flaim JD; Su J; Stein EA; Kastelein JJ
    Am J Cardiol; 2010 May; 105(10):1413-9. PubMed ID: 20451687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Lowering LDL cholesterol frequently does not adhere to guidelines. Also regard intestinal cholesterol source].
    MMW Fortschr Med; 2005 Jun; 147(23):48-9. PubMed ID: 15981908
    [No Abstract]   [Full Text] [Related]  

  • 40. Atherosclerosis target of lipid-lowering therapy: is lower LDL cholesterol better?
    Jones PH
    Am J Manag Care; 2003 Aug; Suppl():1, 4-5. PubMed ID: 13678393
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.